Welcome to our dedicated page for THERIVA BIOLOGICS news (Ticker: TOVX), a resource for investors and traders seeking the latest updates and insights on THERIVA BIOLOGICS stock.
Theriva Biologics Inc (TOVX) is a clinical-stage biotechnology company pioneering oncolytic adenovirus therapies designed to degrade tumor stroma and enhance cancer treatment efficacy. This page provides official updates on clinical developments, research breakthroughs, and strategic initiatives.
Investors and researchers will find a comprehensive collection of press releases, trial result announcements, and regulatory updates related to VCN-01 and other pipeline candidates. Our curated news feed focuses on mechanistically driven advancements in addressing pancreatic, ocular, and other hard-to-treat cancers.
Key updates include progress in systemic delivery methods, partnerships with leading oncology research institutions, and preclinical-to-clinical transition milestones. All content is verified through primary sources to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for timely access to validated information about Theriva Biologics' innovative approach to overcoming treatment resistance through tumor microenvironment modification. Check regularly for new developments in this cutting-edge area of cancer therapeutics.
Theriva™ Biologics (NYSE American: TOVX) has received Rare Pediatric Drug Designation (RPDD) from the U.S. FDA for VCN-01 in treating retinoblastoma. VCN-01, Theriva's lead candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. This follows a previous orphan drug designation for the same indication.
The designation highlights the urgent need for new treatments for pediatric retinoblastoma patients. Theriva is working with physicians and regulators to refine its clinical strategy for VCN-01 as an adjunct to chemotherapy. Recent Phase 1 trial results for intravitreal VCN-01 in refractory retinoblastoma were deemed positive by the study Monitoring Committee.
If VCN-01 receives FDA approval for retinoblastoma, Theriva may be eligible for a Priority Review Voucher, which can be used or sold.
Theriva Biologics (NYSE American: TOVX) announced that the U.S. FDA granted Fast Track Designation (FTD) to its clinical candidate VCN-01 for treating metastatic pancreatic cancer. This designation aims to expedite the drug's development and review process. VCN-01, combined with gemcitabine and nab-paclitaxel, is undergoing a Phase 2b clinical study (VIRAGE) to evaluate its effectiveness as a first-line therapy for pancreatic ductal adenocarcinoma (PDAC). The FDA had previously given orphan drug status to VCN-01 for PDAC. The ongoing VIRAGE trial is expected to complete enrollment by Q3 2024. FTD allows for early and frequent FDA interactions and could speed up the approval process if certain criteria are met.
Theriva Biologics (NYSE American: TOVX) announced its participation in the A.G.P. 2024 Virtual Healthcare Conference. The event is scheduled for May 21, 2024, at 7:30 AM ET. The company's management will provide a corporate update and participate in a fireside chat. Theriva Biologics, a clinical-stage company, focuses on developing therapeutics for cancer and related diseases. The presentation will be available via webcast.
Theriva™ Biologics, a clinical-stage company, reported positive results from a Phase 1 trial for VCN-01 in pediatric patients with retinoblastoma and presented preclinical data on VCN-01's potential in pancreatic cancer treatment. The Phase 2b trial for VCN-01 in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) is expected to complete enrollment soon. The company has $18.3 million in cash as of March 31, 2024, providing runway into Q1 2025.
FAQ
What is the current stock price of THERIVA BIOLOGICS (TOVX)?
What is the market cap of THERIVA BIOLOGICS (TOVX)?
